Year To Quarter End Consolidated Statement Of Comprehensive Income

KYORIN Pharmaceutical Co., Ltd. - Filing #7373032

Concept 2023-04-01 to
2023-09-30
2022-04-01 to
2022-09-30
Year to quarter end consolidated statement of comprehensive income
Statement of comprehensive income
Profit (loss)
1,757,000,000 JPY
1,242,000,000 JPY
Other comprehensive income
Valuation difference on available-for-sale securities
237,000,000 JPY
428,000,000 JPY
Foreign currency translation adjustment
90,000,000 JPY
233,000,000 JPY
Remeasurements of defined benefit plans, net of tax
195,000,000 JPY
183,000,000 JPY
Share of other comprehensive income of entities accounted for using equity method
28,000,000 JPY
-2,000,000 JPY
Other comprehensive income
551,000,000 JPY
841,000,000 JPY
Comprehensive income
2,309,000,000 JPY
2,084,000,000 JPY
Comprehensive income attributable to
Comprehensive income attributable to owners of parent
2,309,000,000 JPY
2,084,000,000 JPY
Comprehensive income attributable to non-controlling interests
JPY
JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.